Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 1227

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 1227
---
,
directors or members of our management team who remain with us may be paid consulting, management or other compensation from the combined
company. All compensation will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender
offer materials furnished to our shareholders in connection with a proposed business combination. It is unlikely the amount of such compensation
will be known at the time because the directors of the post-combination business will be responsible for determining executive officer
and director compensation. Any compensation to be paid to our officers after the completion of our initial business combination will be
determined by a compensation committee constituted solely by independent directors.

We are not party to any agreements with our directors
and officers that provide for benefits upon termination of employment. The existence or terms of any such employment or consulting arrangements
may influence our management’s motivation in identifying or selecting a target business, and we do not believe that the ability
of our management to remain with us after the consummation of our initial business combination should be a determining factor in our decision
to proceed with any potential business combination.

Committees of the Board of Directors

Our board of directors has two standing committees:
an audit committee and a compensation committee. Subject to phase-in rules, the Nasdaq listing rules and Rule 10A-3 of the Exchange Act
require that the audit committee of a listed company be comprised solely of independent directors, and Nasdaq listing rules require that
the compensation committee of a listed company be comprised solely of independent directors. Each committee operates under a charter that
has been approved by our board of directors and has the composition and responsibilities described below. 

Audit Committee

We have established an audit committee of the
board of directors. The members of our audit committee are Catherine Do, G. Sridhar Prasad and Myron W. Shulgan. Mr. Shulgan serves as
chair of the audit committee.

Each member of the audit committee is financially
literate, and our board of directors has determined that Mr. Shulgan qualifies as an “audit committee financial expert” as
defined in applicable SEC rules and has accounting or related financial management expertise.

We have adopted an audit committee charter, which
details the purpose and principal functions of the audit committee, including:

●assisting board oversight of (1) the integrity
of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent registered public
accounting firm’s qualifications and